Altasciences Associates with Wuxi AppTec to Revolutionize WIND...
pharmatechoutlook

Altasciences Associates with Wuxi AppTec to Revolutionize WIND services

By Pharma Tech Outlook | Tuesday, May 21, 2019

Chris Perkin, CEO

FREMONT, CA: A forward-thinking, renowned contract research organization— Altasciences—offering a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept unveiled that they associate with WuXi AppTec’s Investigational New Drug (WIND) platform. WIND provides industry standard CRO services with cross-functional program management and global regulatory expertise to support IND applications. The clinical CRO arm of WuXi AppTec, WuXi Clinical is authorized to be responsible for managing the partnership and ensuring a world-class experience.

The CRO industry is undergoing various mergers and acquisitions, making CROs larger and eliminating competition. With CROs taking their perceived presence in the market for granted may affect customer service. Altasciences is a CRO that provides reliable customer service while working towards delivering a sound platform for early-stage drug development services, bagging a global recognition.

Chris Perkin, the CEO, Altasciences, remarks, “So many CROs say they offer integrated solutions. But the reality is that none of them actually help their clients get from lead candidate selection to proof of concept in a simple coordinated process. We are working on delivering a truly integrated solution that will ultimately change the way early phase outsourcing is managed and executed.”

To support and conduct comprehensive early phase clinical services for WuXi AppTec’s multiple ongoing WIND programs Altasciences will offer its full-service solutions such as clinical pharmacology, premier first-in-human and proof-of-concept trials, program management, medical writing, biostatistics, and data management.

“WuXi AppTec and Altasciences share the same vision, which is to provide a seamless, integrated transition from one key milestone to the next during the early phases of drug development. I am confident that together, we will continue on our path to help sponsors research and develop potentially life-saving therapeutics, faster,” added Perkin.

For over 25 years, Altasciences has been collaborating in its clients’ projects to support educated, faster, and more complete early drug development decisions. Its full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored, to specific sponsor requirements.

Weekly Brief